Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) posted its earnings results on Monday. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.10, FiscalAI reports.
Unicycive Therapeutics Price Performance
Shares of Unicycive Therapeutics stock opened at $3.70 on Wednesday. The firm’s fifty day simple moving average is $4.14 and its 200-day simple moving average is $5.90. Unicycive Therapeutics has a 12 month low of $3.33 and a 12 month high of $8.74. The stock has a market capitalization of $103.05 million, a price-to-earnings ratio of -2.22 and a beta of 1.91.
Wall Street Analyst Weigh In
UNCY has been the subject of a number of research reports. Guggenheim reissued a “buy” rating and issued a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. HC Wainwright cut their target price on Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.25.
Check Out Our Latest Stock Report on UNCY
Unicycive Therapeutics Company Profile
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Read More
- Five stocks we like better than Unicycive Therapeutics
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
